332 related articles for article (PubMed ID: 27181090)
1. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.
Sakai G; Saito D; Nakajima R; Hatano M; Noguchi Y; Kurihara S; Katayama S; Inoue I; Noda M; Shimada A
J Diabetes Investig; 2018 Mar; 9(2):448-449. PubMed ID: 29504279
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
Miyoshi Y; Ogawa O; Oyama Y
Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
[TBL] [Abstract][Full Text] [Related]
5. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
6. Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.
Shiba M; Inaba H; Ariyasu H; Kawai S; Inagaki Y; Matsuno S; Iwakura H; Yamamoto Y; Nishi M; Akamizu T
Intern Med; 2018 Jul; 57(14):2029-2034. PubMed ID: 29491310
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
[TBL] [Abstract][Full Text] [Related]
8. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.
Munakata W; Ohashi K; Yamauchi N; Tobinai K
Int J Hematol; 2017 Mar; 105(3):383-386. PubMed ID: 27696192
[TBL] [Abstract][Full Text] [Related]
9. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
10. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
Matsumura K; Nagasawa K; Oshima Y; Kikuno S; Hayashi K; Nishimura A; Okubo M; Uruga H; Kishi K; Kobayashi T; Mori Y
J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
[TBL] [Abstract][Full Text] [Related]
11. Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.
Jehl A; Cugnet-Anceau C; Vigouroux C; Legeay AL; Dalle S; Harou O; Marchand L; Lascols O; Caussy C; Thivolet C; Laville M; Disse E
Diabetes Care; 2019 Oct; 42(10):2008-2010. PubMed ID: 31434650
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
13. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.
Martin-Liberal J; Furness AJ; Joshi K; Peggs KS; Quezada SA; Larkin J
Cancer Immunol Immunother; 2015 Jun; 64(6):765-7. PubMed ID: 25828465
[TBL] [Abstract][Full Text] [Related]
14. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
Akturk HK; Alkanani A; Zhao Z; Yu L; Michels AW
J Clin Endocrinol Metab; 2018 Oct; 103(10):3589-3592. PubMed ID: 30124874
[TBL] [Abstract][Full Text] [Related]
15. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
Sakaguchi C; Ashida K; Yano S; Ohe K; Wada N; Hasuzawa N; Matsuda Y; Sakamoto S; Sakamoto R; Uchi H; Furue M; Nomura M; Ogawa Y
Curr Oncol; 2019 Feb; 26(1):e115-e118. PubMed ID: 30853818
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies.
Way J; Drakaki A; Drexler A; Freeby M
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978581
[TBL] [Abstract][Full Text] [Related]
18. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
Gauci ML; Boudou P; Baroudjian B; Vidal-Trecan T; Da Meda L; Madelaine-Chambrin I; Basset-Seguin N; Bagot M; Pages C; Mourah S; Resche-Rigon M; Pinel S; Sassier M; Rouby F; Eftekhari P; Lebbé C; Gautier JF
Cancer Immunol Immunother; 2018 Aug; 67(8):1197-1208. PubMed ID: 29808365
[TBL] [Abstract][Full Text] [Related]
20. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
Yamamoto N; Tsurutani Y; Katsuragawa S; Kubo H; Sunouchi T; Hirose R; Hoshino Y; Ichikawa M; Takiguchi T; Yukawa H; Arioka H; Saitou J; Nishikawa T
Intern Med; 2019 Oct; 58(19):2825-2830. PubMed ID: 31243198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
